← All trials
NCT03854396
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2019
- Primary completion
- Feb 29, 2020
- Completion date
- Feb 29, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 58
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of LouisvilleLead sponsor
- University of LouisvilleSponsor investigator
- University of LouisvilleOverall official - principal investigator
- AMAG Pharmaceuticals, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.